Here are some facts for those looking for real answers!
Here are some facts for those looking for real answers! Removed by admin on the pump and dump board!
Among all the inaccurate things that are stated about Cellceutix the top 2 seem to be time line and credibility. Both can be squashed with good DD. Many words have been twisted (some by accident, some by agenda) to try and highlight non issues. As the company moves forward, especially in such a position of success, there will be many that try to mince every word that is written and or said.
Facts -
The company never gave any time line to up-list except one time in an interview saying the plan was for this year (2015) The rumblings that this has lead investors wrong is very inaccurate! As good as Cellceutix has been at keeping investors updated(I for one have appreciated), has also keep the wolves close by the door (the sheep outfits look more and more real I must say!). Giving them the opportunity to smash down every bit of news that is released and turn it in to a non event. So they will keep carrying that torch and may proclaim that partner or up-list is the only way to save the company.The company doesn't require a high SP to conduct and continue through trials this has been discussed ad nausseam! They only thing the attacks on the company have done was drop SP it hasn't slowed anything else down! Well maybe partner discussions, but I don't even think that matters as Cellceutix stands in a position to negotiate anyway.
When your doing your DD find it in print. You will be told things like Phase 2 is meaningless phase 3 is the answer (The same folks say that about everything that has been released) As phase 3 is a given now and just waiting for the "real" time it takes to set up a trial. But if you look at the phase 2 results you will see phase 3 has been very de-risked by the quality of the results. Kevetrin is the same thing phase one took longer than self proclaimed "experts" thought it should. But the quality of the results are outstanding!
Cellceutix isn't a guaranteed success by no means. But if you take a look at where it is, I would much rather be putting my money in a bio with 5 trials, 3 major drugs and phase 2s going on and completed and a phase 3 about to start, over a bio with one drug. Do the math look around compare values of companies.
When you get to money "issue" they have a lot of funding on hand, should they need it. Take a good look at how much the company is burning through! They are using a lot of grants and some trials they are just supplying the drugs.
It is time to take a look at the man behind the mako curtain(it isn't just one) and make a real assessment of the company if you are really considering investing in the company on the long side!
I will only respond to real comments, tomorrow!
Know What you own
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Keep in mind that message boards require you to agree to thier manipulation or you are a lying basher! Also remember those that accuse are often riddle with quilt of performing the same which they accuse.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A New Chapter for PROYA Bet you didn't see this one coming: a leading Chinese beauty brand, PROYA, is throwing its hat into the North American skincare ring, rolling out its science-backed skincare line nationwide at Ulta Beauty. The same brand that's been big news across Asia is now setting its sights on the U.S. with a stunning array of products that don't just promise...
Continue Reading
A Windfall for Career Readiness Here’s a nugget of hope wrapped in a crisp announcement: Genesys Works, the not-for-profit that’s been busy nuancing the work-play balance for high school kids, is rolling with a $4 million boost from Ballmer Group. This move isn’t just pennies from heaven; it's a strategic play designed to gird young folks for the evolving demands of...
Continue Reading
Cracking the Idaho Massage School Code Idaho folks diving into massage therapy education need a playbook—timing, training, and all the bumps along the way. This journey's not just book reading and back rubs; it’s a structured affair with rigid hours and some bureaucratic hurdling. Thank goodness for Kylee Evans, who’s spilling the beans on what goes down in Idaho...
Continue Reading
Seems Lululemon just tripped on its yoga mat. When a company like Lululemon Athletica, Inc (NASDAQ:LULU) sees a 17.38% slide in stock, every savvy investor knows there's more beneath the surface. Squarely in the crosshairs of a securities fraud class action, the brand synonymous with upscale athleisure faces harsh scrutiny. And the deadline's ticking—even the suits know...
Continue Reading
Revving Up: VinFast's Bold Battery Bet Some days it feels like every automaker is just looking for ways to tether drivers to mileage limitations, but VinFast is ripping up the rulebook. Their promise of a 10-year, unlimited-mileage battery warranty has got tongues wagging, and for good reason. Under typical policies, drivers with long commutes or adventurous spirits face...
Continue Reading
Discovering Cangxi's Development Playbook Picture this: a band of African scholars deep-diving into China's rural heartland, Cangxi, in Sichuan province, trying to unlock the secrets behind its impressive cultural and industrial achievements. On November 4, a delegation from the Horn of Africa arrived as part of a training workshop organized by China's Ministry of Foreign...
Continue Reading
CytoSorbents' Financial Turnaround Imagine the smell of fresh opportunity wafting through CytoSorbents’ (NASDAQ:CTSO) corridors this quarter. The company just nudged into positive territory with its operating cash flow, which, let’s be honest, is like finding a nugget of gold amid last year’s rubble of losses. With $43,000 of positive operating cash flow in a world...
Continue Reading
Times are changing, and the digital landscape keeps morphing—who can keep up? That's exactly what's on the agenda as McKenzie Finkhousen and Alton Baird lead HelloNation into the 2026 PHCC of NC Annual Meeting. This ain't just another LinkedIn meet-up—this is a proper gathering of minds in plumbing, heating, and cooling biz right at Harrah's Cherokee Casino Resort....
Continue Reading
The Wine Industry's Digital Splash Ah, the wonderful world of wine—a place where culture, taste, and that sweet bouquet of a well-aged vintage collide. It’s no secret that the wine industry is a cash cow, raking in more than $323 billion annually in the U.S. alone. Digital Information Resources (DIR), a savvy player in tech and media circles, decided this bubbling...
Continue Reading
Understanding the Importance of Year-Round Tax Planning Every small business owner dreads the tax season—like a thunderstorm on a picnic day. But here's a nugget from Paul Kersten, an Accounting and Tax whiz in Shawano, Wisconsin: don't wait until April to sort your taxes. By then, it's all receipts and regrets. Instead, consider tax planning as a year-long vigil. Why?...
Continue Reading
Top 5 Most Recently Viewed Articles
Pagaya Technologies Strengthens Financial Position with Auto ABS Pagaya Technologies LTD. (NASDAQ: PGY), a leading global technology firm, has achieved an important milestone in its journey by successfully closing a substantial $300 million auto asset-backed securitization (ABS) transaction. This notable achievement, labeled RPM 2025-1, reflects Pagaya's innovative...
Continue Reading
Acknowledging Legal Excellence in Dallas Hilgers Graben’s Dallas office continues to make significant strides in the legal community, gaining noteworthy recognition. The managing partner, Grant Schmidt, along with senior counsel Andrew Bean, have both secured a spot on D Magazine’s distinguished list of the 'Best Lawyers Under 40.' This annual accolade celebrates...
Continue Reading
Earning Recognition in the Entrepreneurial Landscape Walker Healthforce, led by the inspiring Tifiany Walker, has made a significant mark in the entrepreneurial scene, recently being honored as a finalist for the Entrepreneur Of The Year 2025 Award. This initiative, celebrating its 40th year, has been the pinnacle of acknowledging business leaders who are not just...
Continue Reading
Positive Phase 1 Results for TML-6 MerryLife Biomedical Inc., an innovative clinical-stage biotechnology company focused on neurodegenerative diseases, recently shared encouraging news about their investigational oral therapy, TML-6, targeting Alzheimer's disease. The recent Phase 1 trial indicated that TML-6 was well-tolerated and exhibited a favorable safety profile,...
Continue Reading
Impressive Quarterly Performance Clariant recently reported exceptional financial performance for the fourth quarter of 2024, showcasing growth across all its business segments. The company achieved sales of CHF 1.091 billion, reflecting a 5% increase in local currency compared to the previous year. This rise in sales can be attributed to a significant volume increase,...
Continue Reading